Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Investment Income: 2020-2024

Historic Non Operating Investment Income for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $150,000.

  • Tango Therapeutics' Non Operating Investment Income fell 129.45% to -$443,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year increase of 60.79%. This contributed to the annual value of $150,000 for FY2024, which is 96.14% down from last year.
  • Per Tango Therapeutics' latest filing, its Non Operating Investment Income stood at $150,000 for FY2024, which was down 96.14% from $3.9 million recorded in FY2023.
  • Tango Therapeutics' 5-year Non Operating Investment Income high stood at $3.9 million for FY2023, and its period low was -$2.9 million during FY2022.
  • Its 3-year average for Non Operating Investment Income is $367,000, with a median of $150,000 in 2024.
  • As far as peak fluctuations go, Tango Therapeutics' Non Operating Investment Income tumbled by 11,271.43% in 2021, and later spiked by 232.35% in 2023.
  • Tango Therapeutics' Non Operating Investment Income (Yearly) stood at $7,000 in 2020, then slumped by 11,271.43% to -$782,000 in 2021, then slumped by 275.96% to -$2.9 million in 2022, then spiked by 232.35% to $3.9 million in 2023, then slumped by 96.14% to $150,000 in 2024.